• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?

作者信息

Giovannoni Gavin

机构信息

Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London E1 2AT, United Kingdom.

出版信息

Mult Scler Relat Disord. 2022 Jul;63:103803. doi: 10.1016/j.msard.2022.103803. Epub 2022 Apr 11.

DOI:10.1016/j.msard.2022.103803
PMID:35487035
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8996445/
Abstract
摘要

相似文献

1
How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?对于接受疾病修饰治疗的多发性硬化症患者而言，新冠病毒疫苗的反应有多重要？
Mult Scler Relat Disord. 2022 Jul;63:103803. doi: 10.1016/j.msard.2022.103803. Epub 2022 Apr 11.
2
Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.不同疾病修正疗法对巴尼特 162b2 疫苗在撒丁岛多发性硬化症患者中体液反应的影响。
Front Immunol. 2021 Dec 9;12:781843. doi: 10.3389/fimmu.2021.781843. eCollection 2021.
3
COVID-19 Vaccine Response in People with Multiple Sclerosis.COVID-19 疫苗对多发性硬化症患者的反应。
Ann Neurol. 2022 Jan;91(1):89-100. doi: 10.1002/ana.26251. Epub 2021 Nov 17.
4
Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.分析利妥昔单抗的使用、利妥昔单抗与 SARS-CoV-2 疫苗接种之间的时间间隔以及多发性硬化症患者 COVID-19 住院或死亡的情况。
JAMA Netw Open. 2022 Dec 1;5(12):e2248664. doi: 10.1001/jamanetworkopen.2022.48664.
5
In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.深入分析特立氟胺或阿仑单抗治疗多发性硬化症患者对 COVID-19mRNA 疫苗接种的长期体液和细胞免疫反应。
Mult Scler Relat Disord. 2023 Apr;72:104616. doi: 10.1016/j.msard.2023.104616. Epub 2023 Mar 12.
6
Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.多发性硬化症的疾病修正治疗与 COVID-19 大流行：感染风险和未来疫苗接种的影响。
CNS Drugs. 2020 Sep;34(9):879-896. doi: 10.1007/s40263-020-00756-y.
7
Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects.干扰素 β-1a 治疗可促进多发性硬化症患者对 SARS-CoV-2 mRNA 疫苗的反应。
Mult Scler Relat Disord. 2022 Feb;58:103455. doi: 10.1016/j.msard.2021.103455. Epub 2021 Dec 18.
8
Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.多发性硬化症患者对 SARS-CoV-2 mRNA 疫苗接种的体液和细胞免疫反应：以色列 3 剂疫苗接种后的多中心经验。
Front Immunol. 2022 Apr 1;13:868915. doi: 10.3389/fimmu.2022.868915. eCollection 2022.
9
COVID-19 vaccines and multiple sclerosis disease-modifying therapies.2019冠状病毒病疫苗与多发性硬化症疾病修正疗法
Mult Scler Relat Disord. 2021 Aug;53:103155. doi: 10.1016/j.msard.2021.103155. Epub 2021 Jul 18.
10
Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.大规模疫苗接种对英国使用免疫调节疾病修正疗法的多发性硬化症患者中 SARS-CoV-2 感染的影响。
Mult Scler Relat Disord. 2022 Jan;57:103458. doi: 10.1016/j.msard.2021.103458. Epub 2021 Dec 5.

引用本文的文献

1
The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.鞘氨醇-1-磷酸受体调节剂对 COVID-19 和 SARS-CoV-2 疫苗接种的影响。
Mult Scler Relat Disord. 2023 Jan;69:104425. doi: 10.1016/j.msard.2022.104425. Epub 2022 Nov 22.

本文引用的文献

1
Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?新冠病毒疫苗接种后的血清转化：我们能否优化 CD20 治疗个体的保护反应？
Clin Exp Immunol. 2022 May 12;207(3):263-271. doi: 10.1093/cei/uxab015.
2
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.在意大利 Delta 和奥密克戎变异株流行期间，接受疾病修正治疗的多发性硬化症患者在感染 COVID-19 后突破性感染 SARS-CoV-2。
EBioMedicine. 2022 Jun;80:104042. doi: 10.1016/j.ebiom.2022.104042. Epub 2022 May 5.
3
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.祖先 SARS-CoV-2 特异性 T 细胞交叉识别奥密克戎变体。
Nat Med. 2022 Mar;28(3):472-476. doi: 10.1038/s41591-022-01700-x. Epub 2022 Jan 14.
4
Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses.由 SARS-CoV-2 感染或 mRNA 疫苗引发的抗体对 Beta 和奥密克戎假病毒的中和活性降低。
Sci Transl Med. 2022 Mar 2;14(634):eabn7842. doi: 10.1126/scitranslmed.abn7842.
5
Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa.南非茨瓦尼一家大医院首次全球奥密克戎变异株 COVID-19 疫情期间疾病严重程度降低。
Int J Infect Dis. 2022 Mar;116:38-42. doi: 10.1016/j.ijid.2021.12.357. Epub 2021 Dec 28.
6
Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.大规模疫苗接种对英国使用免疫调节疾病修正疗法的多发性硬化症患者中 SARS-CoV-2 感染的影响。
Mult Scler Relat Disord. 2022 Jan;57:103458. doi: 10.1016/j.msard.2021.103458. Epub 2021 Dec 5.
7
Pharmacological treatment of COVID-19: an opinion paper.COVID-19 的药物治疗：观点论文。
Rev Esp Quimioter. 2022 Apr;35(2):115-130. doi: 10.37201/req/158.2021. Epub 2021 Dec 11.
8
COVID-19 Vaccine Response in People with Multiple Sclerosis.COVID-19 疫苗对多发性硬化症患者的反应。
Ann Neurol. 2022 Jan;91(1):89-100. doi: 10.1002/ana.26251. Epub 2021 Nov 17.
9
Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.抗 CD20 治疗的多发性硬化症患者对 SARS-CoV-2 疫苗接种的体液和 T 细胞免疫应答不一致。
EBioMedicine. 2021 Nov;73:103636. doi: 10.1016/j.ebiom.2021.103636. Epub 2021 Oct 16.
10
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study.多发性硬化症患者接种辉瑞 BNT162b2 COVID19 疫苗后的体液免疫反应：长达 6 个月的横断面研究。
J Neuroimmunol. 2021 Dec 15;361:577746. doi: 10.1016/j.jneuroim.2021.577746. Epub 2021 Oct 9.